184 related articles for article (PubMed ID: 9704491)
1. Factors determining quality of plasma.
Myllylä G
Vox Sang; 1998; 74 Suppl 2():507-11. PubMed ID: 9704491
[No Abstract] [Full Text] [Related]
2. Plasma fractionation in England and Wales.
Vallet L
Vox Sang; 1972; 23(1):58-60. PubMed ID: 4628157
[No Abstract] [Full Text] [Related]
3. Current approaches to the preparation of plasma fractions.
Vandersande J
Biotechnology; 1991; 19():165-76. PubMed ID: 1786470
[No Abstract] [Full Text] [Related]
4. The development of plasma derivatives in Australia.
Schiff P
Vox Sang; 1972; 23(1):38-43. PubMed ID: 4628156
[No Abstract] [Full Text] [Related]
5. Donor plasmapheresis and regional self sufficiency.
Urbaniak SJ
Int J Artif Organs; 1984 Jan; 7(1):43-6. PubMed ID: 6421755
[No Abstract] [Full Text] [Related]
6. Note for guidance. Guidelines for medicinal products derived from human blood and plasma. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
Biologicals; 1992 Jun; 20(2):159-64. PubMed ID: 1389112
[No Abstract] [Full Text] [Related]
7. The current status of blood fractionation in the United States.
Sgouris JT
Vox Sang; 1972; 23(1):45-55. PubMed ID: 5081014
[No Abstract] [Full Text] [Related]
8. [The sterility of blood products manufactured in Ukraine].
Liubich VV
Lik Sprava; 1992 Feb; (2):57-60. PubMed ID: 1441334
[TBL] [Abstract][Full Text] [Related]
9. Notes on plasma derivative production in the Federal Republic of Germany.
Schwick HG
Vox Sang; 1972; 23(1):44. PubMed ID: 5081013
[No Abstract] [Full Text] [Related]
10. Notes on the production of plasma derivatives in France.
Steinbuch M
Vox Sang; 1972; 23(1):56-7. PubMed ID: 4117049
[No Abstract] [Full Text] [Related]
11. New trends in plasma fractionation.
Steinbuch M
Haematologia (Budap); 1983; 16(1-4):39-51. PubMed ID: 6207083
[No Abstract] [Full Text] [Related]
12. The Dublin Consensus Statement on vital issues relating to the collection of blood and plasma and the manufacture of plasma products. PLUS.
Mahony BO; Turner A
Vox Sang; 2010 Apr; 98(3 Pt 2):447-50. PubMed ID: 20158697
[No Abstract] [Full Text] [Related]
13. ISBT Board response to the Dublin consensus statement.
Flanagan P
Vox Sang; 2011 Feb; 100(2):250-1. PubMed ID: 20946536
[No Abstract] [Full Text] [Related]
14. [Quarantine and plasmapheresis].
Ortiz Pareja M; Terol Fernández E; Hernández Lamas MC; Sánchez Gordo F
Sangre (Barc); 1998 Jun; 43(3):261-2. PubMed ID: 9741240
[No Abstract] [Full Text] [Related]
15. New trends in plasma fractionation and plasma products.
Burnouf T
Vox Sang; 1994; 67 Suppl 3():251-3. PubMed ID: 7975504
[No Abstract] [Full Text] [Related]
16. Chromatographic removal of viruses from plasma derivatives.
Burnouf T
Dev Biol Stand; 1993; 81():199-209. PubMed ID: 8174804
[TBL] [Abstract][Full Text] [Related]
17. GMP in blood collection and processing.
Wagstaff W
Vox Sang; 1998; 74 Suppl 2():513-21. PubMed ID: 9704492
[TBL] [Abstract][Full Text] [Related]
18. Virus inactivation of fresh plasma.
Mohr H
Vox Sang; 1998; 74 Suppl 2():171-2. PubMed ID: 9704442
[No Abstract] [Full Text] [Related]
19. [Plasmapheresis as a method of production of blood fractions].
Lautner A
Bibl Haematol; 1969; 32():212-6. PubMed ID: 5822799
[No Abstract] [Full Text] [Related]
20. [Therapeutic use of hemoderivatives].
Yurrebaso Eguilior N; Mota Villaplana FM; Montoro Ronsano JB
Sangre (Barc); 1997 Oct; 42(5):423-7. PubMed ID: 9424747
[No Abstract] [Full Text] [Related]
[Next] [New Search]
